

AD _____

Award Number: W81XWH 04-1-0082

TITLE: PARK2, a Large Common Fragile Site Gene, is Part of a Stress Response Network in Normal Cells that is Disrupted During the Development of Ovarian Cancer

PRINCIPAL INVESTIGATOR: David I. Smith, Ph.D.

CONTRACTING ORGANIZATION: Mayo Clinic and Foundation
Rochester, MN 55905-0001


REPORT DATE: January 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.



REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE January 2005	3. REPORT TYPE AND DATES COVERED Annual (15 Dec 2003 - 14 Dec 2004)	
4. TITLE AND SUBTITLE PARK2, a Large Common Fragile Site Gene, is Part of a Stress Response Network in Normal Cells that is Disrupted During the Development of Ovarian Cancer			5. FUNDING NUMBERS W81XWH 04-1-0082	
6. AUTHOR(S) David I. Smith, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mayo Clinic and Foundation Rochester, MN 55905-0001 E-Mail: smith.david@mayo.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Original contains color plates: ALL DTIC reproductions will be in black and white				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) PARK2 (Parkin) is an extremely large gene that spans greater than 1.3 megabases of genomic sequence within chromosomal band 6q26. This gene is also derived from within the middle of the highly unstable FRA6E common fragile site (CFS). CFSs are large chromosomal regions that are highly unstable and prone to deletions and other alterations, especially in developing cancer cells. The central two questions that we want to address with this work are what role does the inactivation of Parkin play in the development of ovarian cancer and whether this gene functions as part of a stress response network. In order to address these two questions, we have analyzed the effect of reintroducing Parkin into ovarian cancer cell lines that do not express it. We then demonstrate that the re-introduction of Parkin is associated with greater sensitivity to the induction of apoptosis. This is consistent with our hypothesis that inactivation of this gene contributes to ovarian cancer development. In order to study whether Parkin is part of a stress response network, we have begun to characterize other proteins that Parkin interacts with, including another large CFS gene WWOX. WWOX functions as part of a stress response network and is specifically phosphorylated in stressed cells and then it binds to p53, translocates to the mitochondria and induces apoptosis. We demonstrate specific interactions between Parkin and WWOX; thus Parkin may also be part of a stress response network in normal cells that is disrupted during the development of ovarian cancer.				
14. SUBJECT TERMS Ovarian Cancer				15. NUMBER OF PAGES 25
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	
SF 298.....	1
Table of Contents.....	2
Introduction.....	3
Body.....	3
Key Research Accomplishments.....	12
Reportable Outcomes.....	none
Conclusions.....	12
References.....	none
Appendices.....	13

Introduction

PARK2 is a gene spanning an extremely large chromosomal region of 1.36 Mbs. This large gene spans the most unstable region within the highly unstable FRA6E common fragile site (CFS), and our novel hypothesis that received Department of Defense Ovarian Cancer Research Program funding was that Parkin (and possibly other large CFS genes, including FHIT and WWOX) is part of a stress response system that is disrupted during the development of ovarian cancer. We had three Specific Aims in our proposal. The first goal was to determine if inactivation of Parkin does contribute to the development of ovarian cancer. Our second aim was to inactivate the expression of Parkin, FHIT and WWOX, singly and in combination, in normal ovarian epithelial cells and determine if this had any phenotypic effects on those cells. Our final specific aim was to directly determine if Parkin functions as part of a stress-response network within cells. We proposed to accomplish this by treating VOSE cells with a variety of genotoxic and cellular stresses and then observe the effect on the expression of the Parkin protein. We finally proposed to examine and stress VOSE cells that had FHIT and/or WWOX inactivated to determine if this altered Parkin expression.

Body


We would like to thank the Department of Defense for their support of our work. The study and characterization of common fragile sites has been a difficult field because instability in these regions extends for multiple megabases and the genes in these regions, especially the large genes, have not turned out to be traditional mutational targets in cancer. As a result, there is a notion that CFS regions are merely highly unstable chromosomal positions and that genes in these regions are merely passengers to the instability surrounding them, rather than important players in cancer development. Our laboratory has been working on the cloning and characterization of these regions for many years and it is only with the recent availability of complete genome sequences for humans, mice and rats that important insights about the CFS regions and the genes contained within them have come to light. The CFS regions, in spite of being among the most unstable chromosomal regions, are highly evolutionarily conserved as are the large genes contained within them. The co-conservation of the large genes and the highly unstable regions suggests that the two function together somehow. Complete genomic resources have greatly facilitated the characterization of the CFS regions and we have now localized over 1/3 of the 90 described CFSs. Many of these regions contain genes similar in size to Parkin; thus observations that we make about Parkin, FHIT and WWOX may be applicable to many of large CFS genes. We believe that the entire group of large CFS genes function to respond to different types of stress. In addition, the large CFS genes are highly susceptible to alterations in developing cancer cells and as a group these genes may make significant contributions to the development of ovarian cancer. The current paradigm to explain the development of most epithelial tumors is that alterations in as few as 5-7 tumor suppressors and oncogenes transform normal epithelium into invasive cancer. We believe that these initial alterations trigger increased genomic instability and this then causes alterations in multiple genes, including many of the large CFS genes. These cumulatively cause dramatic changes in the phenotype of the resulting cells, and are also responsible for the tremendous heterogeneity observed in different cancers. We hope to develop sufficient preliminary results from Department of Defense


support so that we can submit more competitive proposals to the National Cancer Institute to further characterize these important chromosomal regions.

In the past year we have made progress on each of the three Specific Aims. We will describe in detail the work that was completed for each Specific Aim.


Specific Aim 1: To analyze the effect of reintroducing PARK2 into ovarian cancer cell lines without endogenous Park2 expression.

We took two ovarian cancer cell lines, OV202 and SKOV3, that had no endogenous Parkin expression and established stable Parkin-expressing cell lines. In addition, we found that Parkin expression was completely abrogated in all of the hepatocellular carcinoma cell lines that we examined, so we also introduced Parkin into two HCC cell lines. After establishing stable Parkin-expressing cancer cell lines, we performed colony formation assays and cell proliferation assays to detect whether Parkin expression would modulate cell growth. The colony formation assays revealed that there was no significant difference between Parkin-expressing clones and vector-only clones; please see the figure below. However, cell proliferation assays showed significant growth retardation in Parkin-expressing clones compared with vector-only clones. These data indicate that Parkin expression can modulate cancer cell growth. The Figures below show the cell proliferation assays comparing Parkin-expressing clones to vector-only clones.





We then analyzed the effect of Parkin expression on cellular response to different stress treatments. We tested ovarian cancer cell lines for the effects of various stress treatments, including DNA damage, chemotherapeutic drugs, and mitochondria-dependent cell death. We observed that Parkin expression had no effect on DNA damage-induced apoptosis, including UV radiation, MMS and MMC-related DNA damage. However, Parkin expression protected cells from mitochondria-dependent apoptosis (ceramide induced apoptosis). The Figure below shows these results.



An aspect of this work was included in a paper that we published last year in *Genes, Chromosomes and Cancer*. The title of the paper was "Parkin gene alterations in Hepatocellular Carcinoma" by Fang Wang, Stacy Denison, Jin-Ping Lai, Leslie A. Phillips, Damien Montoya, Norman Kock, Birgitt Schule, Christine Klein, Viji Shridhar,

Lewis R. Roberts and David I Smith. This paper is included as Appendix 1 of this report. The results in Figure 6 of this paper shows the sensitivity of two HCC cell lines, Hep3B and PLC5, to apoptotic inducers depending upon whether they have a stably transfected Parkin construct or the empty vector. We obtained results identical to this with the two ovarian cancer cell lines. In our original application we also proposed using expression profiling to determine which genes were affected by the re-expression of Parkin. However, we also proposed a similar expression profiling experiment which looked at inactivation of Parkin expression using RNAi strategies. We did the inactivation experiment this year and this will be summarized under the next specific aim.

Specific Aim #2: To use RNAi strategies to inactivate the expression of the three large CFS genes (FHIT, WWOX and Parkin) in normal ovarian epithelial cells.

There were several goals of this Specific Aim. The first goal was to determine if inactivation of multiple large CFS genes produced discernible phenotypic changes to cells. We therefore proposed strategies to inactivate the genes FHIT, Parkin and WWOX, singly and in combination. Our second goal was to use expression profiling to determine other genes affected by the inactivation of these large genes. In the past year we focused our efforts on the second goal. We established stable Parkin-expressing PLC5 (with homozygous Parkin deletion) and then used the U133A Affymetrix chips to compare mRNA levels of approximately 22,000 human genes in cell lines with and without Parkin expression. Parkin expression has been shown to be involved in cell and matrix interaction, so we sought to identify the difference of gene expression when cells were cultured on matrix (matrigel). As we expected, Parkin expression had high effects on gene expression when cultured on matrigel, indicating possible linkage between Parkin and cellular matrix interaction.

Table 1: Differential gene expressions in Parkin expressing and non-expressing PLC5 cells. The table lists the number of genes for which we found varying levels (up 5-fold) of differential expression in Parkin expressing PLC5 cells relative to wild-type PLC5 cells (no Parkin expression) under different growth conditions.

	Up Regulation					Down Regulation				
	2-fold	5-fold	10-fold	20-fold	30-fold	2-fold	5-fold	10-fold	20-fold	30-fold
PLC5/Parkin (Matrigel)	929	89	7	0	0	2376	349	85	8	5
PLC5/Parkin (flask)	956	221	49	8	0	1109	253	51	3	2

Table 2: Partial list of genes with expression level changes >10-fold in Parkin expressing PLC5 under matrix condition (A) and non-matrix condition (B)

A	
Up regulated gene clusters (Matrigel)	Down regulated gene clusters (matrigel)
G-protein coupled receptor 16	endothelin receptor type B
SAR1a gene homolog 1 (S. cerevisiae)	neuro-oncological ventral antigen 1
G-protein coupled receptor for UDP-glucose	class I alcohol dehydrogenase (ADH2) beta-1 subunit
Protein kinase PAK5	protocadherin 8 (PCDH8)
vesicle-associated membrane protein 5	calcium influx channel (htrp3)
tumor necrosis factor receptor member 5	spermatogenesis associated 1 (SPATA1)
Gadd45A	RAP2B, member of RAS oncogene family (RAP2B)
	hyaluronan synthase 2 (HAS2)
	secretogranin III (SCG3)
	cell adhesion molecule with homology to LICAM
	A kinase (PRKA) anchor protein (yotiao) 9
	basic fibroblast growth factor (FGF) 2
	gonadotropin-releasing hormone 1
	zinc finger protein 254
	solute carrier family 16 (monocarboxylic acid transporters)
	transforming growth factor-beta (tgf-beta)
	DEAD box RNA helicase (VASA)
	transient receptor potential cation channel, subfamily C
	suppression of tumorigenicity (ST7)
	fibroblast growth factor (FGF) 20
	matrix metalloproteinase 10
	matrix metalloproteinase 20
B	
Up regulated gene clusters	Down regulated gene clusters
G protein coupled receptor for UDP-glucose	Pentaxin-related gene (induced by IL-1 beta)
Endothelial cell-specific molecule 1	Placental growth hormone
Protein kinase PAK5	uPA receptor
Meningioma expressed antigen 6	parathyroid-like protein
Low density lipoprotein related protein 1B	Chloride channel, calcium activated
secretogranin III (SCG3)	Myosin binding protein C
desmoglein 1	Myogenic factor 5
potassium voltage-gated channel	matrix metalloproteinase 10
heparin binding growth factor 8	TGF-beta receptor 1
regulator of G-protein signaling 9	protocadherin 8 (PCDH8)
integrin beta 6	
Gadd45A	

Specific Aim 3: To determine if Parkin functions as part of a stress response network.

The overall hypothesis that we would like to test is that the entire group of very large CFS genes function together as some type of stress-response network. We originally proposed to just examine the three known large CFS genes at the time (FHIT, Parkin and WWOX). We proposed to treat VOSE cells with various genotoxic and cellular stresses and then observe the effect of these on Parkin expression. We also proposed to observe VOSE cells with WWOX or FHIT inactivation to see if this had any effect on Parkin expression.

In the past year there has been a number of other very large CFS genes discovered. The first one was the 1.46 Mb GRID2 gene at 4q22.3. Michelle Debatisse's group demonstrated that this gene maps to a CFS in both mice and humans. In addition, spontaneous deletions of this gene in mice lead to the mouse mutant Lurcher, which lose 100% of their Purkinje cells postnatally. Interestingly, a spontaneous deletion which removed the Parkin gene and its neighbor PACRG results in another mouse neurological mutant called Quaker (viable).

Since there are a number of extremely large CFS genes, we contacted the University of California, Santa Cruz Human Genome Database to obtain lists of the largest known human, mouse and rat genes. We found that there were far more extremely large genes than anticipated. There are a total of 40 human genes that span greater than 1.0 Mb of genome sequence and another 200 that span between 500 Kb and 1.0 Mb. Interestingly, many of the largest human genes map to chromosomal bands known to contain a CFS. In the past year we have examined several other very large genes, including the 2.3 Mb CNTNAP2 gene, the 2.0 Mb DMD gene, and the 1.5 Mb DAB1 gene. We have discovered that each of these are large CFS genes. Thus far we have found that 6 of the 10 largest human genes are CFS genes. This is extremely important, as anything that we find out with Parkin, FHIT or WWOX may be generalized to all the large CFS genes.

We hypothesized that Parkin might be interacting with other large CFS genes. To test our hypothesis, we tested for possible functional interactions between WWOX and Parkin. The yeast two hybrid experiments revealed that Parkin interacts with wild type WOX1 but not the mutant WOX1 (Y33R). Co-immunoprecipitation confirmed the interaction between WOX1 and Parkin as shown in Figure A. We also observed that Parkin expression specifically decreased wild type WOX1 protein level as shown in Figure B, but did not decrease the expression of mutant WOX1. Moreover, Parkin expression blocked WOX1-induced apoptosis, which was consistent with our previous Specific Aim 1 observation that WOX1-induced apoptosis is mitochondria-dependent and is involved in the p53 and JNK pathway. In addition, Parkin expression protected mitochondrial swelling and blocked WOX1-induced cell death. We also found that Parkin expression markedly reduced the cytosolic protein level of WOX1 (Figure C), and this reduction was abrogated by proteasome inhibitors. This suggests that Parkin, a ubiquitin E3 ligase, may degrade cytosolic WOX1. This is currently under investigation.

Fig. Co-IP of WOX1 and Parkin in COS1 cells




Figure A. Parkin interacts with wild type human WOX1 and mouse WOX1 *in vitro*. To identify the possible interaction of Parkin and WOX1, Parkin-myc and WOX1-GFP plasmids were transfected into COS1 cells, and then total cellular protein was collected and subjected to co-immunoprecipitation. By use of anti-GFP and anti-myc antibody, respectively, we found that Parkin specifically precipitated with human WOX1 and mouse WOX1, not the GFP tag, indicating that Parkin interacts with WOX1 *in vivo*.




Figure B. Parkin expression decreased WOX1 protein level. COS1 cells were transiently transfected with different expression plasmids as indicated in the figure. Cytosol protein was collected and subjected to immunoblotting to detect the expression of GFP-WOX1 varieties in the presence or absence of Parkin. Actin was used as an internal control. Parkin expression reduced the protein level of hWOX1 and mWOX1, but not dominant negative (DN) WOX1 and Y33R mutant WOX1.

Parkin expression decreased the cytosolic level of WOX1 (Figure C). WOX1 is a proapoptotic protein capable of interacting with p53. A large portion of endogenous WOX1 protein is located in the mitochondria, and the mitochondrion-targeting sequence has been mapped within the ADH domain. This is consistent with Parkin's location, as we found a proportion of Parkin was present in mitochondria. During apoptosis or stress responses, there is an increased synthesis of cytosolic WOX1, followed by translocation to the mitochondria. Most conclusively, by electron microscopy we have demonstrated an increased presence of WOX1 in the damaged mitochondria and condensed nuclei of retinal degenerating photoreceptors in rats. Induction of mitochondrial permeability transition by TNF, staurosporine, and atractyloside results in WOX1 release from the mitochondria and subsequent nuclear translocation.

Thus, we assume that the decrease in the cytosolic level of WOX1 by Parkin would block most of the pre-apoptotic function of WOX1, and meanwhile interfere with the translocation of WOX1. We transfected WOX1 and Parkin together into HEK293 cells and detected the cytosolic WOX1 level in the presence or absence of Parkin expression under the treatment of Staurosporine. As shown in Figure C below, without Parkin expression, the cytosolic WOX1 level was abundant. With the staurosporine treatment, cytosolic WOX1 was decreased due to translocation. However, with Parkin expression, we observed decreased cytosolic levels of WOX1 and blockage of translocation of WOX1 under staurosporine treatment. These data represent part of the mechanism by which Parkin blocks WOX1-induced apoptosis.




Figure C: mWOX1 was co-transfected with pcDNA3.1 or Parkin into HEK293 cells. 48hr after transfection, cells were incubated with staurosporine (5 uM) for indicated times, and cytosol was collected by use of NucBuster extraction kit (Novagen). mWOX1 expression was detected by use of anti-GFP Abs, Actin was detected as an internal control.

Key Research Accomplishments

We had three Specific Aims to determine the role that Parkin plays in the development of ovarian cancer. These aims were:

Specific Aim 1: To analyze the effect of reintroducing PARK2 into ovarian cancer cell lines without endogenous Park2 expression.

Specific Aim #2: To use RNAi strategies to inactivate the expression of the three large CFS genes (FHIT, WWOX and Parkin) in normal ovarian epithelial cells.

Specific Aim 3: To determine if Parkin functions as part of a stress response network.

Our key research accomplishments are:

- (1) We have demonstrated that the reintroduction of Parkin into ovarian cancer cell lines (as well as cell lines from other cancers) results in cells that are more sensitive to inducers of apoptosis. This is consistent with our hypothesis that the inactivation of Parkin during the development of ovarian cancer contributes to the cancer phenotype.
- (2) We have begun to demonstrate how Parkin interacts with another very large common fragile site gene, WWOX. Since WWOX has been shown to be functioning as a stress-response gene (this gene is specifically phosphorylated in response to stress and then binds to p53 to induce apoptosis), this provides further evidence that Parkin is also involved in cellular responses to stress.
- (3) We now have evidence that many of the largest human genes (not just FHIT, Parkin and WWOX) are localized within common fragile site regions. The findings that we make with FHIT, Parkin and WWOX may be representative of what is occurring in all of the large CFS genes.

Conclusions

We are continuing to study the very exciting Parkin gene to determine its function in the normal cell and understand how loss of Parkin expression contributes to the development of ovarian cancer. We now know that loss of expression of this gene is associated with greater resistance to induction of apoptosis and that this gene interacts with another large CFS gene, WWOX. In the next year we will be examining how this gene functions to respond to stress. In addition, we will look for more functional connections between Parkin and other large CFS genes involved in stress response.

Appendix

Fang Wang, Stacy Denison, Jin-Ping Lai, Leslie A. Phillips, Damien Montoya, Norman Kock, Birgitt Schule, Christine Klein, Viji Shridhar, Lewis R. Roberts, David I Smith. Parkin Gene Alterations in Hepatocellular Carcinoma. *Genes, Chromosomes, & Cancer* 2004; 40:85-96.

RESEARCH ARTICLE

Parkin Gene Alterations in Hepatocellular Carcinoma

Fang Wang,¹ Stacy Denison,¹ Jin-Ping Lai,² Leslie A. Philips,¹ Damien Montoya,² Norman Kock,³ Birgitt Schüle,⁴ Christine Klein,³ Viji Shridhar,¹ Lewis R. Roberts,² and David I. Smith^{1*}

¹Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota

²Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota

³Departments of Neurology and Human Genetics, University of Lübeck, Lübeck, Germany

⁴Department of Genetics, Stanford University School of Medicine, Stanford, California

The *Parkin* gene is an extremely large gene (1.5 Mb) within the highly unstable FRA6E common fragile site (CFS) region, which is frequently altered in ovarian, breast, and hepatocellular carcinomas. Because *Parkin*/FRA6E has genomic similarities to *FHIT*/FRA3B and *WWOX*/FRA16D, two other large tumor-suppressor genes that are within CFS regions, we were interested in characterizing *Parkin* gene alterations and their possible association with cancer. After analyzing 50 cancer-derived cell lines including 11 hepatocellular carcinoma (HCC) cell lines, we found that one HCC cell line, PLC/PRF/5, had a detectable homozygous deletion encompassing exon 3. Using quantitative duplex PCR and fluorescence in situ hybridization analysis to characterize the copy number changes of *Parkin* exons in HCC cell lines, we found that 4 of 11 HCC cell lines had heterozygous deletions of *Parkin* exons and one, Hep3B, had an exon duplication. *Parkin* protein expression was significantly decreased or absent in all 11 HCC cell lines. Furthermore, more than 50% of HCC primary tumors had decreased *Parkin* expression compared to that in normal liver tissue. *Parkin* gene-transfected PLC5 and Hep3B cells grew more slowly than vector-only transfectants and also showed increased sensitivity to apoptosis induced by cell-cycle inhibitors. Therefore, we suggest that *Parkin* may be involved in tumor suppression and that the loss of *Parkin* contributes to the development of hepatocarcinoma. © 2004 Wiley-Liss, Inc.

INTRODUCTION

The *Parkin* gene was first identified as a mutational (point mutation and exonic deletion) target in a proportion of patients with autosomal recessive juvenile parkinsonism (ARJP) (Hattori, 1998; Kitada et al., 1998; Periquet et al., 2001). The *Parkin* gene contains 12 small exons and encodes an E3 ligase, which is comprised of 465 amino acids with a molecular mass of approximately 52,000 Da. The gene itself is extremely large and spans 1.5 Mb of genomic DNA in chromosomal band 6q26. Various deletions and point mutations in *Parkin* have been discovered in patients with ARJP (Hedrich et al., 2002; Rawal et al., 2003; Tan, 2003). However, large genome rearrangements resulting in the deletion or duplication of *Parkin* exons account for approximately 50% of the alterations observed in patients with ARJP.

The location of *Parkin* is in a chromosomal region that is frequently deleted in multiple tumor types, including hepatocellular carcinoma (HCC), ovarian cancer, and breast cancer. The *Parkin* gene is within FRA6E, the third most active common fragile site (Kahkonen, 1988; Denison et al., 2003a). Common fragile sites (CFSs) are chromosomal loci that are susceptible to forming gaps

and/or breaks when cells are cultured in the presence of specific inhibitors of DNA replication, such as aphidicolin (Rao et al., 1988). The two most active CFSs are FRA3B, at 3p14.2 (Becker et al., 2002), and FRA16D, at 16q23.2 (Mangelsdorf et al., 2000). These CFSs (FRA3B, FRA16D, and FRA6E) also occur in chromosomal regions that are frequently deleted in HCC and many other tumor types (Yuan et al., 2000; Yakicier et al., 2001; Denison et al., 2003a; Huebner et al., 2003). Instability within FRA3B and FRA16D extends for 4.0 and 2.0 Mb, respectively, and spanning the most unstable regions within these CFSs are two extremely large genes, *FHIT* (fragile histidine triad), which is 1.4 Mb (Ohta et al., 1996), and *WWOX* (WW do-

Supported by: NIH; Grant number: CA48031 (to D.I.S.); Department of Defense; Grant number: DAMD 17-99-1-9504 (to D.I.S.); Minnesota Ovarian Cancer Alliance (to D.I.S.); DFG; Grant number: KI-1134/2-2 (to C. K.).

*Correspondence to: David I. Smith, PhD, Professor, Co-director of the Ovarian Cancer Program, Mayo Clinic Cancer Center, Division of Experimental Pathology, Mayo Foundation, 200 First Street SW, Rochester, MN 55905.

Received 19 August 2003; Accepted 28 January 2004

DOI 10.1002/gcc.20020

Published online 26 March 2004 in

Wiley InterScience (www.interscience.wiley.com).

main-containing oxidoreductase), which is 1.0 Mb (Bednarek et al., 2000). Alterations in these two genes are frequently observed in multiple tumor types, and the proteins encoded by these genes are absent or decreased in many different cancers (Lee et al., 2001; Driouch et al., 2002; Yendamuri et al., 2003). However, *FHIT* and *WWOX* do not appear to be traditional mutational targets in cancer because point mutations are rarely found within them, although many tumors have larger heterozygous deletions within the CFS regions that presumably result in inactivation of gene expression.

We recently characterized the FRA6E region and found that instability within this region extended for 3.5 Mb (Denison et al., 2003a). A number of small genes are encoded within the centromeric half of FRA6E, but the distal half, which also contains its most unstable region, is spanned by the 1.5-Mb *Parkin* gene. We found that *Parkin* expression was decreased in 60% of primary ovarian tumors, and we also detected tumor-specific alternative transcripts of *Parkin* in primary ovarian tumors and in ovarian cancer cell lines (Denison et al., 2003b).

Cesari et al. (2003) performed a loss of heterozygosity (LOH) analysis with 40 malignant breast and ovarian tumors and identified a common minimal deleted region, which includes the markers *D6S305* and *D6S1599*. These markers are within the large *Parkin* gene. In addition, they identified a homozygous deletion of exon 2 of *Parkin* in two lung adenocarcinoma cell lines, Calu-3 and H-1573. They also detected absent or diminished *Parkin* expression in breast and ovarian cancer cell lines and in primary tumors.

These three CFS regions and the large genes contained within them, therefore, have a number of similarities. A more detailed analysis of *FHIT* revealed that this gene is inactivated in many tumor types and that the inactivation of this gene can be detected early in cancer development, even in premalignant lesions (Birrer et al., 1999; Hao et al., 2000). The reintroduction of *FHIT* into some, but not all, cancer-derived cell lines can inhibit cell growth and, in some instances, can induce apoptosis (Ji et al., 1999; Sard et al., 1999). Similar alterations have been detected in *WWOX* in multiple tumor types, and cellular stress causes *WWOX* to interact with *P53* to induce apoptosis (Chang et al., 2002, 2003). Hence, these large CFS genes are frequently inactivated in tumors, and their loss can play an important role in tumor development.

We report here on a study in which we examined 11 hepatocellular carcinoma cell lines in a search

for *Parkin* gene alteration. We also observed decreased or absent *Parkin* protein expression in HCC cell lines and primary tumors. Stable expression of the *Parkin* gene in PLC5 and Hep3B HCC cells resulted in enhanced sensitivity to apoptosis induced by cell-cycle inhibitors.

MATERIAL AND METHODS

Reagents

Parkin antibodies were obtained from CellSignaling (Beverly, MA) and Chemicon (Temecula, CA). *Parkin* expression constructs were kindly provided by Dr. Paul J. Lockhart (Mayo Clinic, Jacksonville, FL). Plasmid pcDNA3.1 (\pm)/myc-his A was obtained from Invitrogen (Carlsbad, CA) and was used as a transfection vector-only control. Normal liver tissues and HCC primary tumors were obtained from surgical sections performed at the Mayo Clinic (Rochester, MN). Staurosporine, Trichostatin A (TSA), sodium butyrate, and DAPI were purchased from Sigma-Aldrich (St. Louis, MO).

Cell Culture and Western Blotting Analysis of *Parkin* Expression

The HCC cell lines HepG2, Hep3B, PLC/PRF/5 (PLC5), Huh7, SNU182, SNU387, SNU398, SNU423, SK-Hep1, SNU449, and SNU475 were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and were cultured according to ATCC's protocols. Western blotting was performed according to standard methods. Signals were detected using the ECL system (Amersham Pharmacia Biotech, Piscataway, NJ).

Screening for Homozygous Exonic Deletions in Cancer-Derived Cell Lines

Primers unique for each of *Parkin*'s 12 exons were synthesized according to Kitada (Kitada et al., 1998) at the Mayo Clinic Molecular Core Facility (Rochester, MN) and tested on a DNA panel consisting of genomic DNA isolated from 50 cancer-derived cell lines. Briefly, genomic DNA was isolated from cells by standard phenol-chloroform methods. The PCR mix (20 μ l reaction volume) contained 20 ng of genomic DNA, 1 \times PCR buffer, 2 μ l of dNTP (10 mM), 0.5 μ M primers, and 1 U Taq polymerase (Promega, Madison, WI). The conditions for amplification were: 94°C for 3 min; then 35 cycles of 95°C for 30 sec, 50°C for 30 sec, and 72°C for 30 sec; with a final extension of 72°C for 10 min.

Quantitative Duplex PCR for *Parkin* Gene Dosage Studies in Hepatocellular Cells

To analyze the HCC cell lines for heterozygous deletion (hD), homozygous deletion (HD), or exon duplications, we used quantitative duplex PCR based on the fluorescence resonance energy transfer technique on a LightCycler (Roche Diagnostics, Indianapolis, IN) according to Hedrich et al. (2001). Eleven HCC cell lines and two normal liver tissue samples (positive controls) were used as shown in Table 1. The genomic DNA was isolated using standard phenol-chloroform methods. The PCR samples (20.0 μ l total volume) contained 50 ng of genomic DNA, 1 \times PCR buffer (supplied with enzyme), 4 mM MgCl₂, 0.2 mM dNTP, 0.3 \times Sybr green (Molecular Probes, Inc., Eugene, OR), 0.05% BSA, 0.5 μ M concentration of forward and reverse primers for the specific exons, and 0.1 U Platinum Taq polymerase (Invitrogen, Carlsbad, CA). The conditions for amplification were as previously described. The gene dosage ratio of *Parkin* exons was compared to the control gene β -actin (*HBB*) in order to identify deletions and/or duplications of each exon of *Parkin*. A standard curve was generated by use of human genomic DNA (Roche Diagnostics, Indianapolis, IN) in concentrations of 5, 1.25, and 0.3125 ng/ μ l. All standards (and samples) were amplified in duplicate, followed by calculation of a regression curve, based on which sample concentrations were inferred and accepted only when within the range of the standard templates.

Fluorescence In Situ Hybridization

Metaphase/interphase preparations were obtained from each of the HCC cell lines. Cell harvest and metaphase preparations were performed by routine cytogenetic techniques. Three different bacterial artificial chromosomes (BACs) were used to determine (1) whether any HCC cell line exhibited aneuploidy for chromosome 6 and (2) the *Parkin* dosage level for each cell line. The three BACs were a centromere probe specific to chromosome 6, RP-1 179P19 (which contains a portion of exons 3 and 4 of *Parkin*), and CTD-2643I7 (which contains a portion of *HBB*). For clones RP-1 179P19 and CTD-2643I7, 1 μ g of purified DNA was labeled with biotin-16-dUTP (Boehringer/Roche, Indianapolis, IN) by nick translation, precipitated, and hybridized to the interphase chromosomes according to the protocol described by Verma and Babu (1995). Photomicroscopy was performed with a Zeiss Axioplan 2 fluorescence microscope and

IPLab Spectrum P software (Scanalytics Inc., Fairfax, VA). A minimum of 50 interphase cells were analyzed for each individual HCC cell line.

Sequencing of *Parkin* Transcripts of PLC5 Cells

The total RNA from PLC5 cells was isolated with Trizol reagent (Gibco BRL, Rockville, MD) according to the manufacturer's instructions. To amplify the complete coding region of the *Parkin* gene, 5 μ g of total RNA was subjected to RT-PCR using 3 sets of primers, according to Kuroda (2001). Exons 1–6: forward, 5'-GACCATGATAGT-GTT-3' (nt 98–114); and reverse, 5'-GATGT-TCCG ACTATTTGTTGCGATCAGGT-3' (nt 781–809); exons 2–9: forward, 5'-CTGA GGAAT-GACTG GACTG-3' (nt 249–267); reverse, 5'-CACTCCTCTGCACCAT ACT-3' (nt 1051–1069); and exons 9–12: forward, 5'-GTACAACCGGTACC AGCA GTATG-3' (nt 1034–1056); reverse, 5'-CTA-CACGTCG AACCAGT GGTC -3' (nt 1479–1499). The PCR reactions were performed as above, and the amplified products were cloned into the pCR4-TOPO vector (Invitrogen, Carlsbad, CA) and sequenced by the Molecular Biology Core Facility at the Mayo Clinic, Rochester.

Construction of Stably *Parkin*-Expressing PLC5 and Hep3B Cell Lines

PLC5 and Hep3B cells were maintained in MEM medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum. The *Parkin* expression vector was pcDNA3.1/*Parkin*, and the vector-only control was pcDNA3.1. Before transfection, the exponentially growing cells were washed with serum-free medium and transfected with 5 μ g of plasmids and 20 μ l of Lipofectamin 2000 (Invitrogen) according to the manufacturer's instructions. After a 5-h incubation, complete growth medium was added. After 48 h, transfected cells were selected in 400 μ g/ml Geneticin for 2–3 weeks. Subsequently, cloning cylinders were used to clone individual colonies. For each cell line, eight clones were selected and detected by Western blotting against the *Parkin* antibody. For each *Parkin*-expressing cell line, we chose the three most abundant expressing clones for further study.

Immunocytochemistry Detecting *Parkin* Localization

Parkin-expressing PLC5 and Hep3B cells as well as empty vector transfectants were plated in 4-well chambers in complete growth medium. After 24 hr, cells were washed three times with PBS and fixed in methanol (-20°C) for 10 min, followed by per-

TABLE 1. Homozygous Deletion and Heterozygous Deletion Screening of *Parkin*'s 12 Exons in HCC Cell Lines Using Quantitative Duplex PCR

Cell Line	Ratio <i>PARK2:HBB</i> ^a	Normal ^b	Het. Del. ^c	Het. Dup. ^d	Ex1	Ex2	Ex3	Ex4	Ex5	Ex6	Ex7	Ex8	Ex9	Ex10	Ex11	Ex12
SNU182	1.57	1.3-1.9	0.6-0.9	2.2-2.5	1.44	1.24	1.18	1.49	1.47	1.29	1.44	1.24	1.71	1.43	1.47	1.31
SNU387	1.56	1.3-1.9	0.6-0.9	2.2-2.5	1.28	1.22	1.72	1.18	1.53	1.43	1.5	1.27	1.8	1.39	1.41	1.27
SNU398	0.97	0.8-1.2	0.4-0.6	1.4-1.6	0.61	0.84	0.84	0.56	0.8	0.82	0.74	0.38	0.8	0.89	0.87	0.84
SNU423	1.02	0.8-1.2	0.4-0.6	1.4-1.6	1.13	0.81	0.7	0.73	0.97	0.92	0.9	0.95	0.95	1.02	0.97	0.95
SNU449	0.93	0.8-1.2	0.4-0.6	1.4-1.6	1.12	0.93	1.14	0.94	1.08	0.97	1.05	0.8	1.13	1.09	1.07	1.06
SNU475	0.87	0.7-1.0	0.4-0.5	1.2-1.4	1.05	0.94	1.1	0.81	1.08	0.92	1.04	0.95	1.16	1.11	1.11	1.06
SK-Hep I	0.69	0.6-0.8	0.3-0.4	1.0-1.1	0.69	0.7	0.29	0.54	0.78	0.68	0.95	0.81	0.89	0.72	0.8	0.74
HepG2	1.41	1.1-1.7	0.6-0.8	2.0-2.4	0.93	1.21	1.37	0.95	1.36	1.15	1.32	1.11	1.59	1.37	1.46	1.18
Hep3B	1.73	1.4-2.1	0.7-1.0	2.4-2.8	1.86	1.42	1.83	1.45	2.79	1.48	1.6	1.08	0.94	1.55	1.49	1.38
Huh7	1.50	1.2-1.8	0.6-0.9	2.1-2.4	1.41	0.87	1.1	1.2	1.24	1.33	1.2	1.26	1.54	1.23	1.2	1.13
PLC5 ^e	1.07	0.8-1.2	0.4-0.6	1.4-1.6	1.31	1.08	0.03	0.33	1.34	1.02	1.11	0.72	1.19	1.09	1.1	1.07
Control 1	1.01	0.6-1.2	0.4-0.6	1.4-1.6	0.97	0.99	0.87	0.88	1.15	0.91	0.77	0.83	1.03	1.01	1.04	0.97
Control 2	1.03	0.6-1.0	0.4-0.6	1.4-1.6	0.71	0.8	0.70	0.67	0.92	0.74	0.82	0.74	0.74	0.77	0.87	0.77

The *Parkin* gene dosage ratio was compared to that of the control gene *HBB* (β -actin) and adjusted by FISH. Only one cell line, PLC5, showed an HD of exon 3 and an HD of exon 4; SK-Hep I had an HD of exon 3; SNU398 had an HD of exons 4 and 8; Hep3B had a duplication of exon 5 and an HD of exon 9.

^aThe ratio of hybridization signals observed on interphase nuclei for a BAC (RP1-179P19) containing exons 3 and 4 of the *Parkin* gene compared to that of a BAC (264317) containing a portion of *HBB*.

^bNormal range adjusted for differences in copy number.

^cHeterozygous deletion range based on copy number.

^dHeterozygous duplication range based on copy number.

^eBecause in PLC5 the *Parkin* gene contains a homozygous deletion for exon 3, a BAC (94P15) from another part of the *Parkin* gene was hybridized, and the ratios were calculated.

meabilization with 0.1% Triton X-100 for 5 min. Fixed cells were incubated in 5% normal goat serum for 1 hr and then incubated with anti-Parkin primary antibody at 4°C overnight. Primary antibody was detected after incubation in FITC-conjugated IgG, and the nuclei area was stained with DAPI. Images were viewed with an Axiovert 35 epifluorescence microscope (Carl Zeiss, Thornwood, NY).

Proliferation Assay

Parkin-expressing PLC5 and Hep3B cells and the corresponding vector-only transfected cells were plated at 5,000 cells/well in triplicate in 24-well plates with complete medium. For each cell line, three independent clones were subjected to a proliferation assay. The total cell number was measured every 2 days for a total of 10 days with the MTS assay (Chemicon, Temecula, CA) according to the manufacturer's instructions.

Analysis of Apoptosis

Hep3B and PLC5 cells (*Parkin*-expressing or vector-transfected only) were plated in 6-well plates at a density of 200,000 cells/well. Before treatment, cells were washed with PBS and changed to the serum-free medium. Staurosporine, TSA, and sodium butyrate were added to the serum-free medium at the indicated concentrations and incubated for 5 hr (staurosporine) or 24 hr (TSA and sodium butyrate). Apoptosis was measured by assessing the number of cells containing nuclear changes (chromatin condensation and nuclear fragmentation) after staining with DAPI (final concentration of 5 µg/ml). After incubation in the dark with DAPI for 20 min, cells were examined by fluorescence microscopy (Nikon Eclipse TE200; Nikon Corp., Tokyo, Japan). The experiments were performed in triplicate, and at least 300 cells were counted in each individual treatment.

RESULTS

Screening of 50 Cancer-Derived Cell Lines for Homozygous Deletion of *Parkin* Exons

We screened each *Parkin* exon for homozygous deletion in a panel of 50 cancer-derived cell lines by using genome DNA amplification (data not shown). Only a single cell line, PLC5, had a detectable homozygous deletion of a *Parkin* exon. This cell line exhibited no amplification of exon 3 (Fig. 1A). Sequence analysis of the PCR-amplified cDNA of *Parkin* in the PLC5 cells using three sets of primers specific to exons 1–6, 2–9, and 9–12

confirmed the deletion of exon 3, as the 3' end of exon 2 was directly connected to the 5' end of exon 4 (Fig. 1B).

Quantitative Duplex PCR and FISH for *Parkin* Exon Dosage Studies in HCC Cell Lines

We used quantitative duplex PCR to map possible homozygous (HD) and heterozygous (hD) deletions of *Parkin* gene exons according to Hedrich et al. (2001). This technique was applied to the analysis of the 11 HCC cell lines (including PLC5) for heterozygous deletions and/or duplications of *Parkin* exons. The gene dosage ratio of the *Parkin* gene was compared to the control gene β -actin (*HBB*) in order to identify deletions and/or duplications of whole exons of *Parkin*. The normal gene dosage for any *Parkin* exon as compared to *HBB* was determined to a range of 0.8–1.2. Dosage values less than 0.4, from 0.4 to 0.6, and from 1.4 to 1.6 were identified as representing an HD, hD, and heterozygous duplications, respectively, for that *Parkin* exon. However, these ratios specifically reflected the gene dosage levels for karyotypically normal individual cells.

Karyotypic analysis of primary tumors, as well as of tumor-derived cell lines, has demonstrated that most cancers are aneuploid, with variation in both chromosome number and structure (Knudson, 2001). Hence, we utilized a fluorescence in situ hybridization (FISH)-based technique to quantitate the copy number of 6q sequences surrounding *Parkin* in the HCC cell lines (Fig. 2). We then modified the gene dosage ratios in order to accurately reflect the changes in the gene dosage ratio of *Parkin* exon to *HBB* that could calculate the exon variation observed among the cell lines. We analyzed a total of 50 interphase cells for each of the 11 cell lines in order to determine the ratio of observed hybridization signals of *Parkin* to *HBB* (Table 1). Each HCC cell line had a unique, relatively "normal" *Parkin* gene dosage ratio. For example, for SNU182 cells, the normal ratio is between 1.3 and 1.9, whereas for Hep3B cells the normal ratio is 1.4–2.1.

Quantitative duplex PCR analysis of PLC5 confirmed the HD mapping data and identified PLC5 as having a homozygous deletion of exon 3 (*Parkin*/*HBB* ratio of 0.03; Table 1), as well as a heterozygous deletion of exon 4 (*Parkin*/*HBB* ratio of 0.33; Table 1). SNU398 had a heterozygous deletion of exons 4 and 8, SK-Hep1 had a heterozygous deletion of exon 3, and Hep3B had both a heterozygous duplication of exon 5 and a heterozygous deletion of exon 9 (Table 1).

A Exon 1 2 3 4 5 6 7 8 9 10 11 12



B





Figure 1. Homozygous deletion of exon 3 of *Parkin* gene in PLC5. **(A)** Genomic DNA PCR of 12 exons of *Parkin* gene in PLC5 cells showed the absence of exon 3 **(B)** Quantitative duplex PCR identified that confirmed the exon 3 and exon 4 was deleted in PLC5 cells. The ratio was determined by comparison with the PCR of the control, the *HBB* gene. Exon 3 represents the homozygous deletion and exon 4 was identified as heterozygous deletion.


A

SNU398



B

SNU475



C

SNU182




Figure 2. FISH analyses of HCC cell lines to determine the ratio of *Parkin* exons to *HBB*. Probes for *Parkin* (yellow), *HBB* (red), and the centromere of chromosome 6 (aqua) were hybridized to interphase chromosomes obtained from each cell line. Chromosomal interphases were counterstained with DAPI. All three possible ratios are represented in the figure: **(A)** 1:1 ratio of *Parkin* to *HBB* in SNU398; **(B)** <1:1 ratio of *Parkin* to *HBB* in SNU475; **(C)** >1:1 ratio of *Parkin* to *HBB* in SNU182.

Parkin Protein Expression in HCC Cell Lines and Primary Tumors

Using Western blotting, we found that Parkin protein was completely absent or diminished in all 11 HCC cell lines tested compared with its level in normal liver tissue. As shown in Figure 3A, only SNU423, HepG2, SNU387, and SNU475 had Parkin protein expression. These data were confirmed

using two different Parkin antibodies, which were raised against amino acids 295–311 of human Parkin and full-length Parkin, respectively. We also performed immunoblotting on extracts from HCC primary tumors. We found that more than 50% of primary tumors had diminished or absent Parkin protein expression compared to the benign pair (Fig. 3B).

A.

NL snu423 snu449 Hep3B PLC5 HepG2 snu387 snu475 Huh7 snu182 snu398 SK-hep1



B.

NL1 1 2 3 4 5 6 7 8 9 10 11 12




Figure 3. Western blotting of *Parkin* expression in hepatocellular carcinoma cell lines and primary tumors. (A) *Parkin* antibody recognizes full length of human *Parkin* protein (NL: normal liver). All 11 HCC cell lines show decreased or absent *Parkin* expression compared to normal liver. (B) *Parkin* protein expression in hepatocellular carcinoma primary tumors. 10 of 12 HCC primary tumors show decreased or absent *Parkin* expression.

Growth Retardation and Increased Sensitivity of Apoptosis of *Parkin*-Expressing PLC5 and Hep3B Cells

We selected the PLC5 and Hep3B cell lines into which to reintroduce the *Parkin* gene and to detect potential physiological differences before and after *Parkin* gene expression. We picked up 8 individual clones after transfection and detected *Parkin* protein expression by using Western blotting (Fig. 4A). We chose the three most abundant *Parkin*-expressing clones for use in the proliferation and apoptosis assays. Meanwhile, using immunocytochemistry, we showed that in both the PLC5 and Hep3B transfected cells, *Parkin* protein was mostly localized in the cytoplasm and that there was no colocalization with DAPI (nuclear) (Fig. 4B). Re-

sults were confirmed in PLC5 and Hep3B, two independent *Parkin*-expressing cell lines. This was consistent with other reports that *Parkin* is a cytoplasmic protein.

To determine whether *Parkin* expression affects cell growth, we performed proliferation assays on vector-only PLC5 and Hep3B cells and on three independent *Parkin*-expressing clones of each cell line, PLC5, and Hep3B. In each well of 24-well plates, 5,000 cells were plated, and the MTS assay was used to measure the cell number every 2 days over a 10-day period (Fig. 5). *Parkin*-expressing clones grew more slowly than empty vector transfectants in both the PLC5 and Hep3B cell lines.

To examine the effects of *Parkin* expression on apoptosis, *Parkin*-expressing clones and vector-

A



B




Figure 4. Localization of Parkin protein in stably transfected *Parkin*-expressing PLC5 and Hep3B cells. (A) After *Parkin* gene transfection, eight individual clones derived from each of the cell lines (PLC5 and Hep3B) were subcloned. Western blotting was performed to detect *Parkin* protein expression. (B) Stable *Parkin*-expressing clones were subjected to immunocytochemistry for detection of *Parkin* protein localization using the anti-*Parkin* antibody, which recognizes the full length of the *Parkin* protein. Nuclei were stained with DAPI (blue), and *Parkin* protein was detected with FITC-conjugated secondary antibody (green). In both Hep3B and PLC5 cells, *Parkin* was mostly localized in the cytoplasm. No colocalization with DAPI was detected.

transfected clones were exposed to different treatments. Three apoptosis-inducing drugs were used in the apoptosis induction assay: staurosporine, TSA, and sodium butyrate. Staurosporine is a widely used proapoptotic stimulus that acts as a broad-spectrum kinase inhibitor. Both TSA and sodium butyrate are potent and specific inhibitors of mammalian histone deacetylase, which induce cell apoptosis by regulating the eukaryotic cell cycle. For staurosporine treatment, cells were incubated at concentration ranging from 0 to 5 μ M for 5 h and then stained with DAPI to detect, by fluorescence microscopy, nuclear condensation and fragments, which are evidence of apoptotic cells (Fig. 6). In the other two treatments, the concentrations of TSA ranged from 0 to 1 μ M and of sodium butyrate from 0 to 10 mM. *Parkin* expression had no effect on staurosporine-induced apoptosis. In contrast, *Parkin*-expressing clones were more sensitive to either TSA- or sodium butyrate-induced apoptosis than were vector-transfected clones. The effect was significant at low drug concentrations (TSA at 0.25 and 0.5 μ M, sodium butyrate at 1 and 2 mM). Similar results were obtained in all three PLC5 and all three Hep3B

Parkin-transfected clones. These results showed that *Parkin* enhanced the sensitivity of TSA- and butyrate-induced apoptosis (Fig. 6A–C).

DISCUSSION

Common fragile sites are highly unstable chromosomal regions that predispose chromosomes to breakage and rearrangement (Michels, 1985; Smith et al., 1998). They are present in all individuals, but some are more highly expressed than others. More highly expressed CFSs include FRA3B (3p14.2), FRA16D (16q23.2), and FRA6E (6q26). Interestingly, all three regions were found to be consistently deleted in HCC (Kitay-Cohen et al., 2001; Yalciner et al., 2001; Zhao et al., 2003) as well as in ovarian, breast, and prostate cancers. FRA3B, the most active CFS, spans 4.5 Mb within chromosome segment 3p14.2, and the 1.4-Mb *FHIT* gene is in the center of FRA3B (Ohta et al., 1996). *FHIT* is a diadenosine triphosphate hydrolase whose substrates are produced in cells in response to stress (Brenner et al., 2002). The reintroduction of *FHIT* into specific cancer-derived cell lines results in the induction of apoptosis (Ji et al., 1999; Sard et al., 1999). FRA16D spans 2 Mb and contains the




Figure 5. Proliferation assay of *Parkin*-expressing PLC5 and Hep3B cells. For PLC5 and Hep3B cells, three independent *Parkin*-expressing clones were subjected to the growth assay compared with the vector-only transfectants. The growth rate was detected by MTT assay. The OD value was measured at 550 nm every 2 days for a total of 10 days. The *Parkin*-expressing clones grew more slowly than did the vector-only transfectants.

1.0-Mb *WWOX* gene, which also has been found to be frequently altered in multiple tumor types (Bednarek et al., 2000; Yakicier et al., 2001). Chang et al. (2002, 2003) showed that cellular stress induces phosphorylation of *WWOX* and that this phosphorylated protein functions to induce apoptosis by binding to P53 protein. Hence, both CFS genes appear to play an important role within the cells, and loss of expression of one or both is commonly observed in multiple tumor types, including HCC.

Parkin is the third very large gene that has been mapped within a frequently deleted CFS region (Denison et al., 2003a, 2003b). There are many similarities between *Parkin*/FRA6E, *FHIT*/FRA3B, and *WWOX*/FRA16D. FRA3B, FRA16D, and FRA6E are the three most active CFSs. Instability within each


region extends for 4.0, 2.0, and 3.5 Mb, respectively. Spanning the unstable region within each CFS are extremely large genes comprising relatively small exons, and aberrant transcripts of these genes are frequently observed in tumors. In addition, an absence of expression of all three genes has been observed in HCC and many other tumors.

Polymorphic markers within the large *Parkin* gene showed the highest LOH of any 6q26 markers tested against a panel of primary ovarian tumors (Denison et al., 2003b). Semiquantitative PCR revealed that *Parkin* mRNA was decreased or absent in many ovarian cancer cell lines and primary tumors (Denison et al., 2003b). Recently, Cesari et al. (2003) also identified an altered *Parkin* gene and decreased protein in breast, ovarian, and lung cancer cell lines, and they proposed that *Parkin* was a candidate tumor-suppressor gene.


Parkin was originally identified as a mutational target in patients with autosomal recessive juvenile parkinsonism, a rare form of parkinsonism associated with an early age of onset (Hattori, 1998; Kitada et al., 1998; Periquet et al., 2001). Mutations in *Parkin* have been demonstrated to be responsible for the pathogenesis of ARJP. Patients with ARJP have large deletions or duplications of *Parkin* exons more frequently than point mutations, although 1- or 2-bp, even 40-bp, small-fragment deletions have also been observed in patients (Hattori, 1998; Kitada et al., 1998; Periquet et al., 2001; Hedrich et al., 2002; Rawal et al., 2003; Tan, 2003). These mutations lead to amino-acid substitutions or to truncation of the *Parkin* protein. Mutations have been documented throughout the entire *Parkin* gene, but the majority localize between exons 2 and 8 of *Parkin*, which correspond to the most unstable region within FRA6E.

We tested a panel of 50 cancer-derived cell lines searching for homozygous deletions of *Parkin* exons. One HCC cell line, PLC5, had a detectable homozygous deletion encompassing exon 3 of *Parkin*. We then used the quantitative duplex PCR techniques of Hedrich et al. (2001) to characterize homozygous and heterozygous deletions and duplications of *Parkin* exons in 11 HCC cell lines. This technique was developed to characterize *Parkin* alteration in ARJP patients, who are generally diploid for 6q26 sequences. Because many cancer-derived cell lines are aneuploid, we utilized FISH analysis to determine copy numbers of the 6q26 sequences in the 11 HCC cell lines. We then could use quantitative duplex PCR to standardize the values obtained in order to determine accurately whether there were any deletions or duplications of

A.



B.



C.




Figure 6. *Parkin* expression enhanced the sensitivity of Hep3B and PLC5 cells to apoptosis induced by TSA and sodium butyrate treatments. *Parkin*-expressing cells and vector-only cells were incubated at the indicated concentrations of TSA. After 24 h of incubation, cells were stained with DAPI (5 μ g/ml) for 20 min. Apoptosis percentage was measured by counting the number of cells containing nuclear changes (condensation and fragments). The non-apoptotic cells remain intact. At least three hundred cells were counted, and each experiment was performed in triplicate. (A) Effect of *Parkin*-expression on staurosporine-induced apoptosis. Three independent clones of Hep3B/*Parkin*,

PLC5/*Parkin* cells, and vector-only transfectants were subjected to staurosporine treatment (0, 0.5, 1, 2, and 5 μ M) for 5 h. *Parkin* 1, 2, and 3 refer to three different *Parkin*-expressing clones. (B) Effect of *Parkin* expression on TSA-induced apoptosis. Cells were treated with TSA (0, 0.25, 0.5, 1 μ M) for 24 h. (C) Effect of *Parkin* expression on sodium butyrate-induced apoptosis. Cells were incubated with sodium butyrate (0, 1, 2.5, 5, 10 mM) for 24 h. The apoptosis percentage in three treatments was measured by fluorescence microscopy nuclear counting after DAPI staining.

Parkin exons. The deletions and duplications we found to occur within the "center," which is the most unstable region, of the FRA6E CFS. Most importantly, we found that most of the HCC cell lines and primary tumors had undetectable or decreased *Parkin* protein. However, the molecular mechanism responsible for diminished or absent *Parkin* expression is unknown because only two of the cell lines showed significant changes in the *Parkin* gene. One HCC cell line, PLC5, had a homozygous deletion and the other, Hep3B, an exon duplication. However, it was presumed that instability within the highly unstable, large CFS region may result in multiple deletions and point mutations in the large *Parkin* gene. Aberrant regulation of gene expression may also play a role in the absence of *Parkin* protein.

To determine whether the loss of *Parkin* could play a role in the development of HCC tumors, we generated stable *Parkin*-expressing PLC5 and Hep3B cells. After reintroducing the *Parkin* gene, we measured cell growth and also treated the *Parkin*-expressing cells with apoptosis-inducing drugs. We found slight growth retardation of the two independent PLC5/*Parkin*-expressing and Hep3B/*Parkin*-expressing cells compared to in vector-only transfectants, but no gross growth retardation or cell apoptosis was observed under normal cell culture conditions. We then observed the effects of *Parkin* protein expression on sensitivity to apoptosis after treatments with three drugs. As mentioned above, TSA and sodium butyrate are cell-cycle inhibitors, and staurosporine is a potent kinase inhibitor. We chose to examine the effect of cell-cycle inhibitors because that *Parkin* protein has been shown to bind directly to microtubules and to enhance tubulin degradation (Ren et al., 2003). *Parkin* protein is also recruited to the centrosome in response to the inhibition of proteasomes (Zhao et al., 2003). Centrosome duplication, DNA replication, and cell-cycle regulation are tightly linked, and the balance of microtubule stabilization and destabilization plays an important role in cancer development. We hypothesized that *Parkin* might be involved in cell-cycle regulation, delaying cell-cycle progression under certain cellular stresses. As we expected, *Parkin* expression enhanced the sensitivity of cells to TSA and butyrate treatment, resulting in cell-cycle arrest and increased cell death. In contrast, *Parkin*-expressing cells showed no difference in sensitivity to treatment with staurosporine, as non-*Parkin*-expressing cells and *Parkin*-expressing cells that received staurosporine

treatment showed a similar percentage of apoptotic cells.

Two aspects of these results require particular emphasis. First, *Parkin* protein expression alone did not lead to an increased number of apoptotic cells compared to that in vector-transfected clones. Instead, *Parkin* protein expression enhanced the sensitivity of cells to pro-apoptotic drugs. Second, *Parkin* protein overexpression did not lead to increased sensitivity to all pro-apoptotic induction. This is illustrated by the lack of apoptotic change following staurosporine treatment, in contrast to the enhanced sensitivity to cell-cycle disruption caused by TSA and butyrate. This raises the possibility that *Parkin* is not as broad a tumor-suppressor gene as the *P53* and retinoblastoma genes are. Instead, *Parkin* may show specificity for a certain type of cellular stress.

In this study, we found that *Parkin* is a mutational target in hepatocellular carcinoma, results similar to those previously reported in ovarian and breast cancers. We also found that *Parkin* protein expression was decreased significantly in HCC cell lines as well as in primary tumors. This decreased expression was possibly a result of chromosomal instability and the regulation of gene expression. Further, we showed that *Parkin* increased the sensitivity of cells to apoptosis induced by cell-cycle inhibitors, suggesting that *Parkin* is involved in cell-cycle regulation, possibly through stabilization of microtubules. Because of the striking similarity of *Parkin*, *FHIT*, and *WWOX*, we suggest that *Parkin* could be another tumor-suppressor gene.

REFERENCES

- Becker NA, Thorland EC, Denison SR, Phillips LA, Smith DI. 2002. Evidence that instability within the FRA3B region extends four megabases. *Oncogene* 21:8713-8722.
- Bednarek AK, Lafin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. 2000. *WWOX*, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. *Cancer Res* 60:2140-2145.
- Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ, Geradts J. 1999. Abnormal *Fhit* expression in malignant and premalignant lesions of the cervix. *Cancer Res* 59:5270-5274.
- Brenner C. 2002. *Hint*, *Fhit*, and *GalT*: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. *Biochemistry* 41:9003-9014.
- Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, Drusco A, Shimizu M, Masciullo V, D'Andrilli G, Scambia G, Picchio MC, Alder H, Godwin AK, Croce CM. 2003. *Parkin*, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. *Proc Natl Acad Sci USA* 100:5956-5961.
- Chang NS. 2002. A potential role of p53 and WOX1 in mitochondrial apoptosis (review). *Int J Mol Med* 9:19-24.
- Chang NS, Doherty J, Ensign A. 2003. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. *J Biol Chem* 278:9195-9202.
- Denison SR, Callahan G, Becker NA, Phillips LA, Smith DI. 2003a. Characterization of FRA6E and its potential role in autosomal

- recessive juvenile parkinsonism and ovarian cancer. *Genes Chromosomes Cancer* 38:40–52.
- Denison SR, Wang F, Mueller B, Kock N, Phillips LA, Klein C, Smith DI. 2003b. Genetic alteration in the common fragile site gene PARK2 in ovarian and other cancers. *Oncogene* 22:8370–8378.
- Diouch K, Prydz H, Monese R, Johansen H, Lidereau R, Frengen E. 2002. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. *Oncogene* 21:1832–1840.
- Hao XP, Willis JE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC, Pretlow TP. 2000. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. *Cancer Res* 60:18–21.
- Hattori N, Matsumine H, Asakawa S, Kitada T, Yoshino H, Elibol B, Brookes AJ, Yamamura Y, Kobayashi T, Wang M, Yoritaka A, Minoshima S, Shimizu N, Mizuno Y. 1998. Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene. *Biochem Biophys Res Commun* 249:754–758.
- Hedrich K, Kann M, Lanthaler AJ, Dalski A, Eskelson C, Landt O, Schwinger E, Vieregge P, Lang AE, Breakefield XO, Ozelijs LJ, Pramstaller PP, Klein C. 2001. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. *Hum Mol Genet* 10:1649–1656.
- Hedrich K, Marder K, Harris J, Kann M, Lynch T, Meija-Santana H, Pramstaller PP, Schwinger E, Bressman SB, Fahn S, Klein C. 2002. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. *Neurology* 58:1239–1246.
- Huebner K, Croce CM. 2003. Cancer and the FRA3B/FHIT fragile locus: it's a HIT. *Br J Cancer* 88:1501–1506.
- Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. 1999. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. *Cancer Res* 59:3333–3339.
- Kahkonen M. 1988. Population cytogenetics of folate-sensitive fragile sites. I. Common fragile sites. *Hum Genet* 80:344–348.
- Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature* 392:605–608.
- Kitay-Cohen Y, Amiel A, Ashur Y, Fejgin MD, Herishanu Y, Afanasyev F, Bomstein Y, Lishner M. 2001. Analysis of chromosomal aberrations in large hepatocellular carcinomas by comparative genomic hybridization. *Cancer Genet Cytogenet* 131:60–64.
- Knudson AG. 2001. Two genetic hits (more or less) to cancer. *Nat Rev Cancer* 1:157–162.
- Kuroda Y, Mitsui T, Akaike M, Azuma H, Matsumoto T. 2001. Homozygous deletion mutation of the parkin gene in patients with atypical parkinsonism. *J Neurol Neurosurg Psychiatry* 71:231–234.
- Lee SH, Kim WH, Kim HK, Woo KM, Nam HS, Kim HS, Kim JG, Cho MH. 2001. Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas. *Biochem Biophys Res Commun* 284:850–855.
- Mangelsdorf M, Ried K, Woollatt E, Dayan S, Eyre H, Finnis M, Hobson L, Nancarrow J, Venter D, Baker E, Richards RI. 2000. Chromosomal fragile site FRA16D and DNA instability in cancer. *Cancer Res* 60:1683–1689.
- Michels VV. 1985. Fragile sites on human chromosomes: description and clinical significance. *Mayo Clin Proc* 60:690–696.
- Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T. 1996. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. *Cell* 84:587–597.
- Periquet M, Lucking C, Vaughan J, Bonifati V, Durr A, De Michele G, Horstink M, Farrer M, Illarioshkin SN, Pollak P, Borg M, Brefel-Courbon C, Deneffe P, Meco G, Gasser T, Breteler MM, Wood N, Agid Y, Brice A. 2001. Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects. *Am J Hum Genet* 68:617–626.
- Rao PN, Heerema NA, Palmer CG. 1988. Fragile sites induced by FUDR, caffeine, and aphidicolin. Their frequency, distribution, and analysis. *Hum Genet* 78:21–26.
- Rawal N, Periquet M, Lohmann E, Lucking CB, Teive HA, Ambrosio G, Raskin S, Lincoln S, Hattori N, Guimaraes J, Horstink MW, Dos Santos Bele W, Broussolle E, Destee A, Mizuno Y, Farrer M, Deleuze JF, De Michele G, Agid Y, Durr A, Brice A. 2003. New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism. *Neurology* 60:1378–1381.
- Ren Y, Zhao J, Feng J. 2003. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. *J Neurosci* 23:3316–3324.
- Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, Pierotti MA, Sozzi G. 1999. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. *Proc Natl Acad Sci USA* 96:8489–8492.
- Smith DI, Huang H, Wang L. 1998. Common fragile sites and cancer (review). *Int J Oncol* 12:187–196.
- Tan LC, Tanner CM, Chen R, Chan P, Farrer M, Hardy J, Langston JW. 2003. Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation. *Mov Disord* 18:758–763.
- Verma R, Babu A. 1995. Human chromosomes: principles and techniques. New York: McGraw-Hill.
- Yakicier MC, Legoix P, Vaury C, Gressin L, Tubacher E, Capron F, Bayer J, Degott C, Balabaud C, Zucman-Rossi J. 2001. Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. *Oncogene* 20:5232–5238.
- Yendamuri S, Kuroki T, Trapasso F, Henry AC, Dumon KR, Huebner K, Williams NN, Kaiser LR, Croce CM. 2003. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. *Cancer Res* 63:878–881.
- Yuan BZ, Keck-Waggoner C, Zimonjic DB, Thorgerisson SS, Popescu NC. 2000. Alterations of the FHIT gene in human hepatocellular carcinoma. *Cancer Res* 60:1049–1053.
- Zhao J, Ren Y, Jiang Q, Feng J. 2003. Parkin is recruited to the centrosome in response to inhibition of proteasomes. *J Cell Sci* 116:4011–4019.
- Zhao P, Song X, Nin YY, Lu YL, Li XH. 2003. Loss of fragile histidine triad protein in human hepatocellular carcinoma. *World J Gastroenterol* 9:1216–1219.